Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited

和黃醫藥 (中國) 有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 13)

MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF 45% EQUITY INTEREST IN SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

TIMING OF DISPATCH OF CIRCULAR

Reference is made to the announcement of HUTCHMED (China) Limited (the "Company") dated January 1, 2025 (the "January 1 Announcement") in relation to the proposed disposal of 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the January 1 Announcement.

In the Company's announcement dated January 28, 2025, it was mentioned that the Circular containing, among other things, (i) further details on the terms of the Proposed Disposal; and (ii) other information as required under the Listing Rules together with a notice convening the EGM, was expected to be dispatched to the Shareholders on or before February 28, 2025.

GP Health Service Capital has further informed the Seller that the designation to the GP Purchaser Fund and the Designated Purchaser is progressing but additional time is required for them to complete the designation. In view of this, the Company currently expects that the Circular will be dispatched to the Shareholders on or before March 31, 2025.

The Proposed Disposal is subject to all of the conditions under the Agreements being satisfied (or, if applicable, waived) and therefore may or may not become unconditional. If any of the conditions under the Agreements is not satisfied (or, if applicable, waived), the Proposed Disposal will not proceed. Shareholders and potential investors are reminded to exercise caution when dealing in the shares and other securities of the Company.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, February 28, 2025

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director:

Dr Dan ELDAR

Executive Directors:

Dr Weiguo SU
(Chief Executive Officer and
Chief Scientific Officer)
Mr CHENG Chig Fung, Johnny
(Chief Financial Officer)

Non-executive Directors:

Ms Edith SHIH Ms Ling YANG

Independent Non-executive Directors:

Mr Paul Rutherford CARTER
(Senior Independent Director)
Dr Renu BHATIA
Dr Chaohong HU
Mr Graeme Allan JACK
Professor MOK Shu Kam, Tony